Gilead Sciences GILD
NASDAQ GILD
$150.11 -0.78 (-0.52%)
At close: Sep 18, 2026 · 4:00 PM EDT

Gilead Sciences (GILD) Income towards Parent Company (2009 - 2026)

Gilead Sciences' (GILD) quarterly Income towards Parent Company came in at -$10.5 billion in Q2 2026, down 635.24% on a YoY basis from $2.0 billion in Q2 2025, and down 619.35% quarter-over-quarter from $2.0 billion in Q1 2026.

Analysis

Gilead Sciences (GILD) Income towards Parent Company (2009 - 2026) Analysis & Trends

Gilead Sciences (GILD) has reported Income towards Parent Company for 18 consecutive years, with -$10.5 billion the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Income towards Parent Company fell 635.24% year-over-year to -$10.5 billion; the trailing twelve-month figure through Jun 2026 stood at -$2.9 billion (down 145.87% YoY), and the FY2025 full-year result was $8.5 billion, up 1676.62% from the prior year.
  • Income towards Parent Company slipped to -$10.5 billion in Q2 2026 per GILD's latest filing, from $2.0 billion in the prior quarter.
  • Across five years, Income towards Parent Company topped out at $3.1 billion in Q3 2025 and bottomed at -$10.5 billion in Q2 2026.
  • Historically, Income towards Parent Company has averaged $613.2 million across 5 years, with a median of $1.5 billion in 2023.
  • The sharpest annual moves came in 2023 and 2026: Income towards Parent Company surged 8100.0% in 2023, then slumped 635.24% in 2026.
  • Over 5 years, Income towards Parent Company stood at $1.6 billion in 2022, then fell by 13.29% to $1.4 billion in 2023, then grew by 25.85% to $1.8 billion in 2024, then surged by 41.86% to $2.5 billion in 2025, then tumbled by 515.19% to -$10.5 billion in 2026.
  • According to Business Quant data, Income towards Parent Company over the past three periods registered -$10.5 billion, $2.0 billion, and $2.5 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 208.48 Bn 194.49 Bn 7.24 Bn
2 Gilead Sciences 186.29 Bn 183.02 Bn 6.22 Bn
3 Vertex Pharmaceuticals 128.79 Bn 120.93 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 80.66 Bn 72.67 Bn 3.93 Bn
5 Moderna 61.46 Bn 56.32 Bn 52.00 Mn
6 Argenx Se 61.28 Bn 56.10 Bn 1.37 Bn
7 Alnylam Pharmaceuticals 32.04 Bn 28.73 Bn 992.69 Mn
8 Biogen 31.84 Bn 30.56 Bn 1.96 Bn
9 Roivant Sciences 28.74 Bn 29.43 Bn 1.16 Mn
10 Insmed 26.19 Bn 25.03 Bn 358.27 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -10.50 Bn
Mar 31, 2026 2.02 Bn
Dec 31, 2025 2.53 Bn
Sep 30, 2025 3.05 Bn
Jun 30, 2025 1.96 Bn
Mar 31, 2025 1.32 Bn
Dec 31, 2024 1.78 Bn
Sep 30, 2024 1.25 Bn
Jun 30, 2024 1.62 Bn
Mar 31, 2024 -4.17 Bn
Dec 31, 2023 1.42 Bn
Sep 30, 2023 2.17 Bn
Jun 30, 2023 1.04 Bn
Mar 31, 2023 984.00 Mn
Dec 31, 2022 1.63 Bn
Sep 30, 2022 1.79 Bn
Jun 30, 2022 1.14 Bn
Mar 31, 2022 12.00 Mn
Dec 31, 2021 376.00 Mn
Sep 30, 2021 2.59 Bn